COMPOUND； COMPOSITION； METHOD OF TREATMENT AND / OR PREVENTION OF MIGRAINE, ALS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, EXTRAPYRIMIDAL DISORDERS, DEPRESSION, NAUSEA, AEMESIS, SYNDROME OF THE WASTE LEGS, INSOMENESS, HYGERNESS, AGING , ANXIETY, DRUG DEPENDENCIES, DYSTONIA, PARASSONIA OR HYPERLACTINEMIA IN AN INDIVIDUAL； AGONIZATION METHODS OF D2, 5-HT1D, 5-HT1A AND 5-HT2C RECEPTORS, IN AN INDIVIDUAL； ANTAGONIZATION METHOD OF THE D3 RECEPTOR IN AN INDIVIDUAL； METHODS OF SELECTIVE AGONIZATION OF RECEPTORS 5 -HT1D, AND 5-HT2C, METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN RECEPTOR 5 -HT2
ergoline compounds and pharmaceutical compositions thereof are provided, as well as the use of such compounds and pharmaceutical compositions in methods of treating, preventing or ameliorating a variety of medical disorders, such as migraine； receptor agonization methods, such as 5-ht1a, 5-ht1b and 5-ht1d receptors, without 5-ht2b receptor agonization； alpha2a and / or alpha2b adrenergic receptor antagonizing methods； and methods of d2 and d3 receptor antagonization.são fornecidos compostos de ergolina e composições farmacêuticas dos mesmos, bem como o uso desses compostos e composições farmacêuticas em métodos de tratamento, prevenção ou melhora de uma variedade de distúrbios médicos, tais como enxaqueca； métodos de agonização de receptores, tais como os receptores 5-ht1a, 5-ht1b e 5-ht1d, sem a agonização do receptor 5-ht2b； métodos de antagonização dos receptores 5-ht2b adrenérgico alfa2a e/ou alfa2b； e métodos de antagonização do receptor d2 e d3.
